Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

FDA places clinical hold on phase II IMO-3100 trial

July 21, 2011

Galderma discloses novel androgen receptor antagonists

July 21, 2011

Allergan enters definitive agreement to acquire Vicept Therapeutics

July 20, 2011

Graceway Pharmaceuticals gains FDA approval for Zyclara cream

July 20, 2011

Janssen Pharmaceuticals to divest U.S. Ortho Dermatologics division

July 19, 2011

Photocure begins enrollment in new phase II Visonac study

July 19, 2011

Leo Pharma and The Scripps Research Institute enter collaboration for treatment of skin diseases

July 18, 2011

ATX-101 is safe and reduces submental fat in phase II trial

July 13, 2011

Briakinumab is superior to etanercept in treating chronic plaque psoriasis

July 13, 2011

Adalimumab is beneficial in hidradenitis suppurativa in phase II study

July 13, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...